Double 5-fluorouracil modulation with folinic acid and recombinant alpha- 2B-interferon

A Phase I-II study in metastatic colorectal cancer patients

I. Brunetti, A. Falcone, M. Bertuccelli, C. Cianci, S. Ricci, P. F. Conte

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty-two patients with metastatic colorectal cancer entered a Phase I- II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination. Diarrhea and mucositis were the most frequent 5- fluorouracil-related toxicities and were ≥ECOG grade 3 in 23% and 18% of patients, respectively. Of 15 patients receiving interferon ≥9 x 106 IU, 10 required interferon dose reduction mostly because of severe fatigue, anorexia, and declining performance status. Among 19 patients evaluable for response, 3 achieved a partial response and 1 a complete response for an overall response rate of 21% (95% confidence interval, 6-46%). In conclusion, our study demonstrates that IFN-α2B at doses higher than 6 x 106 IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5- fluorouracil plus folinic acid without IFN-α. A larger Phase III study would be required to determine the value of IFN-α in this combination.

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number3
Publication statusPublished - 1994

Fingerprint

interferon alfa-2b
Leucovorin
Fluorouracil
Colorectal Neoplasms
Interferons
Mucositis
Poisons
Anorexia
Fatigue
Diarrhea
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Double 5-fluorouracil modulation with folinic acid and recombinant alpha- 2B-interferon : A Phase I-II study in metastatic colorectal cancer patients. / Brunetti, I.; Falcone, A.; Bertuccelli, M.; Cianci, C.; Ricci, S.; Conte, P. F.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 3, 1994, p. 210-214.

Research output: Contribution to journalArticle

@article{d7564fa0d0e347bf9f28d8b5d7b4e4f5,
title = "Double 5-fluorouracil modulation with folinic acid and recombinant alpha- 2B-interferon: A Phase I-II study in metastatic colorectal cancer patients",
abstract = "Twenty-two patients with metastatic colorectal cancer entered a Phase I- II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination. Diarrhea and mucositis were the most frequent 5- fluorouracil-related toxicities and were ≥ECOG grade 3 in 23{\%} and 18{\%} of patients, respectively. Of 15 patients receiving interferon ≥9 x 106 IU, 10 required interferon dose reduction mostly because of severe fatigue, anorexia, and declining performance status. Among 19 patients evaluable for response, 3 achieved a partial response and 1 a complete response for an overall response rate of 21{\%} (95{\%} confidence interval, 6-46{\%}). In conclusion, our study demonstrates that IFN-α2B at doses higher than 6 x 106 IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5- fluorouracil plus folinic acid without IFN-α. A larger Phase III study would be required to determine the value of IFN-α in this combination.",
author = "I. Brunetti and A. Falcone and M. Bertuccelli and C. Cianci and S. Ricci and Conte, {P. F.}",
year = "1994",
language = "English",
volume = "17",
pages = "210--214",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Double 5-fluorouracil modulation with folinic acid and recombinant alpha- 2B-interferon

T2 - A Phase I-II study in metastatic colorectal cancer patients

AU - Brunetti, I.

AU - Falcone, A.

AU - Bertuccelli, M.

AU - Cianci, C.

AU - Ricci, S.

AU - Conte, P. F.

PY - 1994

Y1 - 1994

N2 - Twenty-two patients with metastatic colorectal cancer entered a Phase I- II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination. Diarrhea and mucositis were the most frequent 5- fluorouracil-related toxicities and were ≥ECOG grade 3 in 23% and 18% of patients, respectively. Of 15 patients receiving interferon ≥9 x 106 IU, 10 required interferon dose reduction mostly because of severe fatigue, anorexia, and declining performance status. Among 19 patients evaluable for response, 3 achieved a partial response and 1 a complete response for an overall response rate of 21% (95% confidence interval, 6-46%). In conclusion, our study demonstrates that IFN-α2B at doses higher than 6 x 106 IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5- fluorouracil plus folinic acid without IFN-α. A larger Phase III study would be required to determine the value of IFN-α in this combination.

AB - Twenty-two patients with metastatic colorectal cancer entered a Phase I- II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination. Diarrhea and mucositis were the most frequent 5- fluorouracil-related toxicities and were ≥ECOG grade 3 in 23% and 18% of patients, respectively. Of 15 patients receiving interferon ≥9 x 106 IU, 10 required interferon dose reduction mostly because of severe fatigue, anorexia, and declining performance status. Among 19 patients evaluable for response, 3 achieved a partial response and 1 a complete response for an overall response rate of 21% (95% confidence interval, 6-46%). In conclusion, our study demonstrates that IFN-α2B at doses higher than 6 x 106 IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5- fluorouracil plus folinic acid without IFN-α. A larger Phase III study would be required to determine the value of IFN-α in this combination.

UR - http://www.scopus.com/inward/record.url?scp=0028332043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028332043&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 210

EP - 214

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -